Skip to main content
NewslettersWatchlist

Fibrogen Inc CS(FGEN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low1.1200
Day High1.2100
Open:1.2000
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
AllPennyStocks.com
Traders Rush To Buy Biotech Following Q1 Earnings Beat
Barchart
Stocks Move Higher Before the Open as Investors Await Key U.S. GDP Data, Salesforce Earnings on Tap
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN
Motley Fool
Down 80% in 1 Day, Is There Any Hope for FibroGen Stock?
PR Newswire
Bassem Elmankabadi, M.D. joins Foresee Pharmaceuticals as a Senior Vice President of Clinical Development
MarketBeat
Why did Sarepta Therapeutics Stock Plummet?
Barchart
Chart of the Day: FibroGen - Bio Tech
Business Wire
FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Provides Update of its Investigation of the Officers and Directors of FibroGen, Inc. - FGEN
Globe Newswire
FibroGen Reports Second Quarter 2022 Financial Results
PR Newswire
FIBROGEN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Provides Update of its Investigation of the Officers and Directors of FibroGen, Inc. - FGEN
Globe Newswire
FibroGen to Report Second Quarter 2022 Financial Results
Business Wire
FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Provides Update of its Investigation of the Officers and Directors of FibroGen, Inc. - FGEN
Globe Newswire
FibroGen to Participate at William Blair Biotech Focus Conference 2022
Globe Newswire
FibroGen Announces Completion of Patient Enrollment in LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Duchenne Muscular Dystrophy
Business Wire
FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of FibroGen, Inc. - FGEN
Globe Newswire
FibroGen to Present at Jefferies Healthcare Conference
Globe Newswire
FibroGen Reports First Quarter 2022 Financial Results
Business Wire
FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of FibroGen, Inc. - FGEN
Business Wire
FIBROGEN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of FibroGen, Inc. - FGEN
Globe Newswire
FibroGen to Report First Quarter 2022 Financial Results
Globe Newswire
FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-1, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
Globe Newswire
FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results
Globe Newswire
FibroGen to Report Fourth Quarter and Full Year 2021 Financial Results
Globe Newswire
FibroGen to Present at SVB Leerink 11th Annual Global Healthcare Conference
Globe Newswire
FibroGen Exercises Exclusive License Option for HiFiBiO’s CCR8 Program
Business Wire
FIBROGEN ALERT: Bragar Eagel & Squire, P.C. Is Investigating Fibrogen, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Business Wire
Blade Therapeutics Appoints Bassem Elmankabadi, M.D., as Senior Vice President of Clinical Development
Globe Newswire
FibroGen Reports Third Quarter 2021 Financial Results
Globe Newswire
FibroGen to Present at Upcoming Investor Conferences
Globe Newswire
FibroGen to Report Third Quarter 2021 Financial Results

Profile

FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019 which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. FibroGen, Inc. is headquartered in San Francisco, California.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.